Herbalife Ltd. provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers products in the areas of weight management; targeted nutrition; energy, sports, and fitness; outer nutrition; and literature and promotional items. The company also provides weight management products, including meal replacement products, protein shakes, drink mixes, weight loss supplements, healthy snacks, and metabolism boosting teas; targeted nutrition products, which comprise functional beverages, and dietary and nutritional supplements that contain herbs, vitamins, minerals, and other natural ingredients; outer nutrition products, such as facial skin, body, and hair care products; and energy, sports, and fitness products, including N-R-G tea and energy drink products. In addition, it offers literature, promotional, and other materials that comprise start-up kits, sales tools, and educational materials. The company sells its products through sales representatives, independent service providers, and company-operated retail platforms. Herbalife Ltd. was formerly known as Herbalife Nutrition Ltd. and changed its name to Herbalife Ltd. in April 2023. The company was founded in 1980 and is headquartered in Los Angeles, California.

Herbalife looks like a company with a cheap valuation based on earnings and cash flow, but with a very heavy balance sheet and a weak equity base. A P/E of 7.09, P/S of 0.22, and P/FCF of 3.55 are noticeably below the industry median, which usually supports the idea of undervaluation and limits the potential for a sharp de-rating. At the same time, P/B is extremely high because of negative shareholders’ equity, and that is an important signal that a classic balance-sheet valuation is not very informative here and instead highlights structural risk. Gross margin is very strong and remains stable at around 77.7%, while operating margin of 9.46% is even above the industry median, which points to decent operating discipline. However, net margin of 3.15% is noticeably weaker than the industry and has deteriorated compared with higher levels in previous periods, so earnings quality remains average. ROA and ROI look acceptable, but the one-year trend in ROI and ROA is weaker than before, indicating gradual pressure on capital efficiency. EPS and forecast EPS do not look poor, but current profitability does not show convincing acceleration that would justify a higher multiple. Revenue and gross profit are growing, which is a positive, but the growth is not strong enough to fully offset the weakness of the balance sheet. Long-term debt of about $2.0 billion, combined with negative equity and total liabilities above $3.3 billion, creates notable financial risk and limits the market’s appetite for a re-rating. Liquidity, with a current ratio of 1.20 and a quick ratio of 0.74, remains only adequate, with no real cushion. The dividend yield of 6.89% looks attractive for an income-oriented investor, but it does not offset the balance-sheet risks and may be viewed as compensation for elevated uncertainty. Overall, the fundamentals present a mixed picture: the operating model is still generating profit and cash flow, but weak capital, high leverage, and deteriorating net margin limit the potential for fair-value expansion. Therefore, the target forecast should be moderately reduced, while maintaining a cautious view on the stock and recognizing that the current low valuation already partly reflects the risks.

Herbalife Ltd.

Сильный индекс, значительно упал. Быки в растерянности.

Strong index, significantly down. The bulls are confused.

Слабый индекс, значительно упал. Рынок не поддерживает быков.

Weak index, significantly down. The market does not support the bulls.

Слабый индекс, незначительно упал. Приток средств в лонги остался положительным, но снизился.

Weak index, slightly down. The inflow of funds into longs remained positive, but decreased.

HLF looks cheap on earnings and FCF, but negative equity, high debt, and a weak net margin limit its revaluation potential.

(RTTNews) - Herbalife (HLF) announced that Stephan Gratziani will transition from his role as Chief Executive Officer, effective October 31, 2026. Gratziani will continue supporting Herbalife as a consultant focused on strategy and business development. He will also return his primary focus to his independent distributorship of nearly 700,000 distributors and preferred members. John DeSimone, CFO, will serve as Interim Chief Executive Officer beginning November 1, 2026. The Board has formed a committee to oversee the succession process for Gratziani.
DeSimone has been with Herbalife for nearly 20 years as an advisor, partner, and mentor across the organization. In addition to serving as CFO, he has served in senior leadership positions including President, Chief Strategy Officer, and Special Advisor to the CEO.
In pre-market trading on NYSE, Herbalife shares are down 1.29 percent to $12.27.
For More Such Health News, visit rttnews.com.

Herbalife Announces CEO Transition; John DeSimone To Serve As Interim CEO

For Immediate Release
Chicago, IL – August 28, 2026 – Stocks in this week’s Herbalife Ltd. HLF, Honda Motor HMC, Marathon Petroleum Corp. MPC, Halozyme Therapeutics HALO and Genworth Financial GNW.
5 Value Stocks to Buy Right Now as Inflation Remains Sticky
Wall Street is entering a period of renewed uncertainty as sticky inflation complicates the Federal Reserve’s stance on interest rates. U.S. inflation remains well above the central bank’s 2% target, while the prolonged conflict in the Middle East continues to create risks for energy prices and the broader economy.
With the next Fed decision approaching and September historically proving a challenging month for stocks, investors may face greater volatility ahead. This backdrop makes chasing expensive growth stocks less appealing.
Instead, investors may benefit from focusing on companies whose share prices do not fully reflect their underlying fundamentals. Value investing could offer a sensible approach in this environment, as financially solid businesses trading at reasonable valuations may provide a stronger margin of safety while giving investors room to benefit if market sentiment improves.
Value investors can consider stocks such as Herbalife Ltd., Honda Motor, Marathon Petroleum Corp. Halozyme Therapeutics and Genworth Financial, which have high earnings yield.
Understanding Earnings Yield Metric
One metric widely used by value investors to identify potentially undervalued stocks is earnings yield. Calculated by dividing a company’s annual earnings per share by its current stock price, earnings yield indicates the amount of earnings generated for every dollar invested in a stock. Generally, a higher earnings yield suggests a stock may be undervalued relative to its earnings potential, while a lower earnings yield can indicate a richer valuation.
Earnings yield also provides a useful way to compare stocks with fixed-income investments such as bonds. When a stock’s earnings yield exceeds prevailing bond yields, it may offer a more attractive return potential, making it a valuable tool for investors searching for opportunities in an uncertain market.
Here we have discussed five of the 35 stocks that qualified the screening:
Herbalife is a global nutrition company focused on helping consumers improve their health and wellness through science-based products.The Zacks Consensus Estimate for HLF’s 2026 and 2027 EPS implies year-over-year growth of 26% and 12%, respectively. While EPS estimates for the current year have remained stable over the past 30 days, they have moved up by 18 cents for 2027 over the same timeframe. Herbalife currently carries a Zacks Rank #2 and has a Value Score of A.
Hondais a leading manufacturer of automobiles and the largest producer of motorcycles in the world.The Zacks Consensus Estimate for HMC’s fiscal 2027 and 2028 EPS implies year-over-year growth of 204% and 62%, respectively. EPS estimates for the current year and the next have moved up by $1.27 and 67 cents, respectively, over the past 30 days. Honda currently sports a Zacks Rank #1 and has a Value Score of A.
Marathon Petroleum is a leading independent refiner, transporter and marketer of petroleum products. The Zacks Consensus Estimate for MPC’s 2026 EPS implies year-over-year growth of 336%. EPS estimates for the current year and the next have moved up by $3.47 and $2.29, respectively, over the past 30 days. Marathon Petroleum currently carries a Zacks Rank #2 and has a Value Score of A.
Halozyme is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting the tumor microenvironment. The Zacks Consensus Estimate for HALO’s 2026 and 2027 EPS implies year-over-year growth of 97% and 18%, respectively. EPS estimates for the current and next year have moved up by 23 cents and 9 cents, respectively, over the past 30 days. Halozyme currently carries a Zacks Rank #2 and has a Value Score of B.
Genworth, through its principal insurance subsidiaries, offers mortgage and long-term care insurance products. The Zacks Consensus Estimate for GNW’s 2026 and 2027 EPS implies year-over-year growth of 214% and 5%, respectively. EPS estimates for the current and next year have moved up by 66 cents and 69 cents, respectively, over the past 60 days. Genworth currently carries a Zacks Rank #2 and has a Value Score of A.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
For the rest of this Screen of the Week article please visit Zacks.com at:
https://www.zacks.com/stock/news/2981136/5-value-stocks-to-buy-right-now-as-inflation-remains-sticky
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).

Zacks.com featured highlights Herbalife, Honda Motor, Marathon, Halozyme and Genworth

Herbalife Ltd (HLF) came out with quarterly earnings of $0.51 per share, missing the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -19.05%. A quarter ago, it was expected that this company would post earnings of $0.55 per share when it actually produced earnings of $0.64, delivering a surprise of +16.36%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Herbalife Ltd, which belongs to the Zacks Retail - Pharmacies and Drug Stores industry, posted revenues of $1.33 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.06%. This compares to year-ago revenues of $1.26 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Herbalife Ltd shares have lost about 0.7% since the beginning of the year versus the S&P 500's gain of 13%.
What's Next for Herbalife Ltd?
While Herbalife Ltd has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Herbalife Ltd was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.70 on $1.3 billion in revenues for the coming quarter and $2.68 on $5.2 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Pharmacies and Drug Stores is currently in the top 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the broader Zacks Retail-Wholesale sector, Advance Auto Parts (AAP), is yet to report results for the quarter ended June 2026. The results are expected to be released on August 20.
This auto parts retailer is expected to post quarterly earnings of $0.81 per share in its upcoming report, which represents a year-over-year change of +17.4%. The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level.
Advance Auto Parts' revenues are expected to be $2.03 billion, up 1.2% from the year-ago quarter.
Should You Invest in Herbalife Ltd (HLF)?
Before you invest in Herbalife Ltd (HLF), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Herbalife Ltd (HLF) : Free Stock Analysis Report
Advance Auto Parts, Inc. (AAP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Herbalife Ltd (HLF) Q2 Earnings Lag Estimates

Key Points
142,919 shares sold directly for a total of ~$1.93 million, based on a weighted average price of $13.52 per share on May 11 and May 12, 2026.
The transaction represented 79.60% of Lamberti's direct holdings, reducing his direct stake from 179,543 to 36,624 shares.
No indirect or derivative involvement; all shares sold were directly owned common stock.
This is Lamberti's only open-market sale since at least August 2023, accounting for the entirety of his net share disposals during the period, with remaining capacity now limited.
Frank Lamberti, Chief Commercial Officer of Herbalife Ltd. (NYSE:HLF), reported the direct sale of 142,919 common shares across two transactions on May 11 and May 12, 2026, for a total estimated value of ~$1.93 million according to the SEC Form 4 filing.
Transaction summary
Shares sold (direct)
142,919
Transaction value
~$1.93 million
Post-transaction shares (direct)
36,624
Post-transaction value (direct ownership)
~$499K
Transaction value based on SEC Form 4 weighted average purchase price ($13.52); post-transaction value based on May 12, 2026 market close price.
Key questions
What proportion of Lamberti's direct equity position was sold in this transaction?
This sale accounted for 79.60% of his direct holdings, reducing the position from 179,543 shares to 36,624 shares.
Was this activity linked to any derivative exercise, indirect holdings, or affiliated entities?
No; the disposition involved only directly held common shares, with no options exercised and no shares held through trusts, LLCs, or other entities after the transaction.
How does this compare to Lamberti's historical trading activity in Herbalife?
This is the sole open-market sale by Lamberti since at least August 2023; prior filings were administrative (grant/withholding) events with no change to net holdings.
What is the context for timing and remaining capacity?
The transaction occurred after an 93.06% one-year price increase (as of May 12, 2026), and with just 20.4% of his pre-sale shares remaining, further large-volume sales would require additional vesting or grants.
Company overview
Revenue (TTM)
$5.13 billion
Net income (TTM)
$239.80 million
Price (as of market close 5/12/26)
$13.52
1-year price change
93.06%
* 1-year price change calculated using May 12th, 2026 as the reference date.
Company snapshot
Offers a portfolio of nutrition products, including meal replacements, protein shakes, dietary supplements, energy drinks, and personal care items, with weight management and targeted nutrition as primary revenue drivers.
Operates a direct-selling business model, distributing products primarily through independent service providers and sales representatives, complemented by company-operated retail platforms.
Targets health-conscious consumers seeking nutrition, wellness, and weight management solutions across North America, Latin America, EMEA, China, and Asia Pacific regions.
Herbalife Nutrition Ltd. is a global nutrition company with a broad geographic footprint and a focus on science-based products for weight management and wellness. The company leverages a direct-selling model, enabling scalable distribution and strong engagement with end consumers. Herbalife's strategy centers on product innovation and expanding its network of independent distributors to maintain competitive advantage in the consumer nutrition sector.
What this transaction means for investors
Lamberti’s sale of Herbalife stock comes after the first significant rebound in the stock since the end of the pandemic. The stock had struggled post-pandemic amid declining sales, leading to a decline of more than 70% over the last five years.
Herbalife stock continues to trade at a considerable discount to those highs earlier in the decade. Nonetheless, the stock rebounded by 93.06% over the previous year amid recovering sales growth. In the first quarter of 2026, net sales rebounded by 8%, well above the 1% gain in 2025.
Although the filing does not reveal why Lamberti sold shares, the fact that he sold 79.6% of his direct holdings may be a cause for concern among investors.
This does not mean the rally has come to an end. Moreover, it sells at a P/E ratio of 6, a low level even when considering that its P/E ratio was 14 five years ago. Still, considering that Herbalife stock has pulled back since Lamberti sold shares, investors have to wonder whether the recent pullback in the consumer discretionary stock will continue.
Should you buy stock in Herbalife right now?
Before you buy stock in Herbalife, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Herbalife wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $462,983!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,375,447!*
Now, it’s worth noting Stock Advisor’s total average return is 995% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 3, 2026.
Will Healy has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Chief Commercial Officer Sells 143,000 Shares of Herbalife for $1.9 Million

Breaking Down Jamie Dimon’s Investing Letter

An updated edition of the January 13, 2026, article.
The health and fitness industry has grown from a niche segment into a powerful global movement, driven by a broad shift toward healthier lifestyles. Consumers are no longer content with occasional exercise — they increasingly seek balanced nutrition, structured workout routines and well-rounded wellness solutions. Demand is rising across gyms, dietary supplements and personalized programs, while technological advances have made managing personal health easier and more engaging. Wearable devices, fitness platforms and virtual coaching services now provide real-time insights, tailored guidance and ongoing motivation. At the same time, greater awareness of obesity, chronic illnesses and mental health has strengthened the emphasis on preventive, everyday wellness.
Major technology companies are helping accelerate this transformation. Apple AAPL, through its Apple Watch ecosystem and Fitness+ platform, integrates activity tracking with guided workout experiences. Amazon AMZN is expanding its presence in healthcare via One Medical, combining AI-powered tools with virtual care services to enhance accessibility and convenience. Together, these innovations are reshaping how individuals approach wellness, blending fitness, healthcare and daily life while driving industry growth.
Market forecasts highlight the scale of this opportunity. The global health and wellness market is expected to reach $11 trillion by 2034 at a steady 5.4% CAGR from 2025. Preventive healthcare initiatives, workplace wellness programs and supportive policy measures continue to boost demand. Meanwhile, specialized offerings — such as boutique fitness studios and premium wellness clubs — reflect a broader, more holistic focus on physical, nutritional and mental well-being. This evolving landscape is creating fresh growth opportunities for companies like Garmin Ltd. GRMN, Herbalife Ltd. HLF and American Well Corporation AMWL.
For investors, the takeaway is clear: wellness represents a durable, long-term theme. As consumers place greater priority on their health, demand for fitness, nutrition and digital health solutions is likely to stay strong. Our Health & Fitness Screen highlights key companies in this space — including the three mentioned above — helping investors identify opportunities in a market poised for sustained growth.
Ready to uncover more transformative thematic investment ideas? Explore 37 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.
3 Health & Fitness Stocks to Buy Now
Garmin develops a wide range of GPS-enabled and sensor-based devices designed for people who live active lifestyles. Its offerings span several markets, including fitness, outdoor recreation, aviation and marine navigation. Within the health and fitness category, Garmin provides running watches under the Forerunner series, cycling computers, smartwatches, heart-rate monitors, smart scales and other performance-tracking tools. These products monitor metrics such as activity levels, workouts and wellness data, while the Garmin Connect digital platform allows users to track progress, analyze training results and interact with a broader fitness community.
Over the years, Garmin has expanded its fitness ecosystem by integrating advanced sensors, navigation capabilities and cloud-based software into its devices. Many products combine satellite navigation systems with biometrics, activity tracking and health monitoring features to support running, cycling and other athletic pursuits. The Zacks Rank #1 (Strong Buy) company has also developed related accessories and indoor training equipment, such as smart trainers and connected bike systems, allowing users to measure performance and improve training outcomes across different sports environments. You can see the complete list of today’s Zacks #1 Rank stocks here.
Garmin’s continued investment in research and development has enabled it to introduce new products and features while improving existing devices. Its vertically integrated design and manufacturing capabilities allow engineering and production teams to collaborate closely, helping bring innovations to market more quickly. As consumer demand for wearable technology and performance tracking tools grows, Garmin continues to position its products as reliable tools that support healthier, more active lifestyles worldwide.
Herbalife is a global nutrition company focused on helping consumers improve their health and wellness through science-based products. The #1 Ranked company sells a wide range of offerings, including weight-management shakes, protein supplements, functional beverages, vitamins and sports nutrition products. Its product portfolio also includes energy drinks and skincare items designed to support active lifestyles and overall well-being. These products are distributed in dozens of markets through a direct-selling network of independent members who provide coaching and guidance to customers pursuing nutrition and fitness goals.
Over time, Herbalife has expanded its offerings to address changing consumer preferences for healthier living. The company continues to develop new products and improve existing ones through internal research teams and collaborations with scientific advisors and universities. Recent initiatives include new metabolic health products, healthier snack options and nutrition formulas designed to support long-term wellness and cellular health. These innovations are intended to help consumers meet evolving dietary needs and maintain active lifestyles.
Herbalife’s business model also emphasizes community-based engagement around nutrition and fitness. Through programs such as nutrition clubs, fitness camps and wellness evaluations led by independent members, the company promotes daily product consumption alongside lifestyle coaching. These initiatives encourage ongoing interaction between distributors and customers while supporting broader health and fitness goals. Combined with continuous product development and global distribution, these efforts have helped Herbalife remain a prominent participant in the wellness and nutrition industry.
American Well Corporation, widely known as Amwell, is a digital healthcare platform focused on expanding the virtual delivery of care across a wide range of settings. Its primary offerings include enterprise telehealth software, clinical services through Amwell Medical Group and the Converge platform, which connects patients, providers and payers within a unified ecosystem. By facilitating services such as primary care, behavioral health, chronic condition management and wellness coaching, Amwell operates at the intersection of healthcare and the broader health and fitness landscape. These capabilities make medical advice, mental health support and lifestyle guidance more accessible through a digital-first approach.
Amwell has evolved from a traditional telehealth provider into a more comprehensive digital care platform. The launch of Converge integrated previously separate services, simplifying access for health systems, insurers and employers. This integration has enabled expansion into chronic disease management, preventive care and wellness programs. The Zacks Rank #2 (Buy) company has also broadened its specialty services, particularly in behavioral health and remote patient monitoring, while strengthening partnerships with leading healthcare organizations. These developments highlight Amwell’s transition into a platform that not only addresses immediate care needs but also promotes long-term health and wellness.
In recent years, Amwell has taken steps to strengthen its financial position while continuing to invest in innovation. Cost-reduction initiatives, divestitures of non-core assets and a greater focus on scaling the Converge platform have helped streamline operations. At the same time, the company has introduced new digital tools, expanded collaborations with third-party service providers and enhanced patient engagement features. Together, these efforts underscore Amwell’s commitment to delivering holistic health solutions. By integrating clinical care, lifestyle support and advanced technology, the company has positioned itself as a key enabler of digital wellness, aiming to remain at the forefront of the evolving health and fitness-focused market.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Best Health & Fitness Stocks to Buy Now for Strong Growth

(RTTNews) - Herbalife Ltd. (HLF), a health and wellness company, reported revenue growth for the fourth quarter and full year 2025. The company also expects improved revenue for fiscal 2026.
Following the news, HLF surged above 14% at $18.95 in the overnight market.
For the fourth quarter, adjusted net income increased to $47.5 million from $36.8 million a year ago.
Adjusted diluted EPS jumped to $0.45 from $0.36 in the year-ago period.
However, net income attributable to Herbalife declined to $85.4 million from $ 177.9 million in the last year.
On a per-share basis, net income slipped to $0.81 from $1.74 in the prior year.
Adjusted EBITDA of $156.1 million from $150.1 million in the prior year.
Net sales increased 6.3% to $1.28 billion from $1.21 billion in the prior year. This exceeds the guidance for 1.5% to 5.5% growth for the fourth quarter of 2025.
For the full year 2026, adjusted net income climbed to $219.4 million from $198.9 million in the prior year.
Adjusted diluted EPS increased to $2.12 from $1.96 in the last year.
However, net income attributable to Herbalife declined to $228.3 million from $254.3 million in the prior year.
On a per share basis, net income slipped to $2.20 from $2.50 in the year ago.
Adjusted EBITDA improved to $657.6 million from $634.8 million a year ago.
Net sales for the full year were up 0.9% to $5.04 billion from $4.99 billion in the prior year. This exceeds the full-year sales guidance range of negative 0.3% to 0.7%, which was tightened in November 2025 from the earlier 1% to 3% range provided in August 2025.
Looking ahead, for the first quarter of 2026, Herbalife expects revenue on a reported basis to increase 3% to 7% from $1.221.7 million in the year-ago period.
On a reported basis, Adjusted EBITDA is expected to be in the range of $155 to $175 million compared with $164.9 million a year ago.
For the full year 2026, Herbalife expects net sales on a reported basis to increase in the range 1 % to 6% from $5037.5 million in 2025.
Adjusted EBITDA is expected to be in the range of $670 million to $710 million versus $657.6 million reported in 2025.
HLF has traded between $5.57 and $17.93 in the last 1 year. The stock closed Wednesday's trade at $16.54, up 3.76%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Herbalife Q4 Revenue Improves; Sees Higher Revenue For FY26

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Herbalife (HLF) Q4 2025 Earnings Call Transcript

Herbalife Ltd (HLF) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post earnings of $0.47 per share when it actually produced earnings of $0.5, delivering a surprise of +6.38%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Herbalife Ltd, which belongs to the Zacks Retail - Pharmacies and Drug Stores industry, posted revenues of $1.28 billion for the quarter ended December 2025, missing the Zacks Consensus Estimate by 14.47%. This compares to year-ago revenues of $1.21 billion. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Herbalife Ltd shares have added about 23.7% since the beginning of the year versus the S&P 500's zero return.
What's Next for Herbalife Ltd?
While Herbalife Ltd has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Herbalife Ltd was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.70 on $1.3 billion in revenues for the coming quarter and $2.51 on $5.4 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Pharmacies and Drug Stores is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the broader Zacks Retail-Wholesale sector, Sweetgreen, Inc. (SG), has yet to report results for the quarter ended December 2025. The results are expected to be released on February 26.
This company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -24%. The consensus EPS estimate for the quarter has been revised 13.4% lower over the last 30 days to the current level.
Sweetgreen, Inc.'s revenues are expected to be $159.69 million, down 0.8% from the year-ago quarter.
Should You Invest in Herbalife Ltd (HLF)?
Before you invest in Herbalife Ltd (HLF), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Herbalife Ltd (HLF) Misses Q4 Earnings and Revenue Estimates

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AST SpaceMobile Inc (Symbol: ASTS), where a total volume of 81,604 contracts has been traded thus far today, a contract volume which is representative of approximately 8.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 53% of ASTS's average daily trading volume over the past month, of 15.4 million shares. Particularly high volume was seen for the $80 strike call option expiring January 02, 2026, with 5,184 contracts trading so far today, representing approximately 518,400 underlying shares of ASTS. Below is a chart showing ASTS's trailing twelve month trading history, with the $80 strike highlighted in orange:
Herbalife Ltd (Symbol: HLF) options are showing a volume of 10,917 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 50.8% of HLF's average daily trading volume over the past month, of 2.2 million shares. Especially high volume was seen for the $12.50 strike put option expiring December 18, 2026, with 4,074 contracts trading so far today, representing approximately 407,400 underlying shares of HLF. Below is a chart showing HLF's trailing twelve month trading history, with the $12.50 strike highlighted in orange:
And Starbucks Corp. (Symbol: SBUX) saw options trading volume of 46,073 contracts, representing approximately 4.6 million underlying shares or approximately 49.7% of SBUX's average daily trading volume over the past month, of 9.3 million shares. Particularly high volume was seen for the $100 strike put option expiring January 16, 2026, with 10,897 contracts trading so far today, representing approximately 1.1 million underlying shares of SBUX. Below is a chart showing SBUX's trailing twelve month trading history, with the $100 strike highlighted in orange:
For the various different available expirations for ASTS options, HLF options, or SBUX options, visit StockOptionsChannel.com.
Also see:
RXO YTD Return
VRTX DMA
AEP Price Target
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Periodand min./max. price, $	Price change, %		Volatility, %		Volume, $
Periodand min./max. price, $	HLF	Industry	HLF	Industry	Volume, $
Yesterday 11.9 - 12.5	2.71	0.08	8.43	1.57	10.76M
Week 11.9 - 13.2	6.55	0.69	2.34	1.95	67.31M
Month 10.4 - 13.2	5.85	4.95	8.94	4.84	314.59M
3 Months 10.4 - 13.5	3.87	0.76	35.57	10.01	940.92M
6 Months 10.4 - 17.5	-15.89	0.05	46.27	15.88	1.77B
Year 7.6 - 20.4	37.83	1.45	59.24	25.82	3.86B
3 years 5.0 - 20.4	-11.87	3.08	111.59	52.46	9.84B
5 years 5.0 - 49.1	-73.35	5.01	137.65	74.97	20.65B
All time 3.0 - 61.8	97.34	24.98	—	—	27.79B

Herbalife Ltd.

Price and volatility history

Risk ratios